New Specialty Biochemical plant inaugurated by Godavari Biorefineries Ltd
10.6.2024 14:10:00 EEST | Business Wire | Press release
A new specialty biochemical plant has been inaugurated at the Sakarwadi manufacturing facility in Maharashtra, India where Godavari Biorefineries Limited (GBL) intends to produce biobased chemicals to support the green and net-zero ambitions of its clientele in different markets across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240607431453/en/
Inauguration of new specialty biochemical plant at the Sakarwadi manufacturing facility in Maharashtra, India (Photo: Business Wire)
GBL has taken a next step with the intention to support the world’s ambition for net-zero strategies by developing a multi-purpose plant which aims to produce biobased chemicals for coatings & resins, cosmetics, pharmaceuticals and food & fragrances markets.
“At GBL we make Specialty Chemicals from Renewable Resources using Green Chemistry. We work with farmers to develop sustainable agricultural value chains that serve as a feedstock for our biobased chemicals,” said Samir Somaiya, Chairman of Somaiya Group andGodavari Biorefineries Ltd.
This multi-purpose plant is one of the steps GBL has taken to support and partner with leading companies to enlarge the amount of biobased chemical blocks in the chemical industry for different markets and products, and intends to produce biochemicals like biobutanol, biobased ethers and esters in this plant. GBL has the strategy to further develop and scale-up its capacity in the coming years in volumes and for new biobased chemicals.
“We work in close relation and collaboration with our customers to develop and produce new biobased chemical building blocks in several markets. In co-creation we work from R&D to pilot scale towards the (semi-)commercial scale of new biobased chemicals into several applications and products that can become biobased and green. It is a journey towards net-zero where we are open for new partnerships and new insights, and define pathways to take together,” said Sangeeta Srivastava, CEO of Godavari Biorefineries Ltd.
GBL is a flagship company of the diversified Somaiya group with an experience of over eight decades in the sugar industry and over six decades in the biobased chemicals industry. We work with our farmers in sugarcane and other biomass crops to create value for their communities and our customers' value chains.
Padma Vibhushan Prof. M. M. Sharma, a luminary in the field of chemical engineering, performed the ribbon-cutting ceremony and delivered an inspiring address. He highlighted the critical role of R&D in the chemical industry and complimented GBL efforts in establishing a plant that represents the future of specialty chemicals manufacturing.
For information please visit: http://godavaribiorefineries.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240607431453/en/
Contact information
E-mail: dhansoia.pushpendra@somaiya.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom